

# Oleg V Averkov

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3837381/oleg-v-averkov-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

|                   |                       |                |                 |
|-------------------|-----------------------|----------------|-----------------|
| 20<br>papers      | 713<br>citations      | 6<br>h-index   | 23<br>g-index   |
| 23<br>ext. papers | 935<br>ext. citations | 5.7<br>avg, IF | 3.34<br>L-index |

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 20 | NEWS2, 4C Mortality Score, COVID-GRAM, Sequential Organ Failure Assessment Quick scales as outcomes assessment tools for severe COVID-19 (pilot retrospective cohort study). <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , <b>2022</b> , 21, 3103                                    | 0.9  | 0         |
| 19 | Morphine and Clinical Outcomes in Patients with ST segment elevation Myocardial Infarction Treated with Fibrinolytic and Antiplatelet Therapy: Insights from the TREAT Trial.. <i>American Heart Journal</i> , <b>2022</b> , 251, 1-1  | 4.9  | 1         |
| 18 | Gastrointestinal Bleeding: a Cardiologist's Point of View. <i>Rational Pharmacotherapy in Cardiology</i> , <b>2021</b> , 17, 771-778   | 0.5  |           |
| 17 | Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk. <i>Russian Journal of Cardiology</i> , <b>2021</b> , 26, 4305                                   | 1.3  |           |
| 16 | COVID-19 infection after recent heart transplantation: a case report. <i>Russian Journal of Cardiology</i> , <b>2020</b> , 25, 3904  | 1.3  | 2         |
| 15 | Reprofiling of a multispecialty hospital into an infectious hospital and the work under coronavirus pandemic conditions <b>2020</b> , 25-40  |      | 1         |
| 14 | IgM and IgG antibodies against SARS-CoV-2 in neonates born to mothers with COVID-19. <i>Bulletin of Russian State Medical University</i> , <b>2020</b> , 28-30   | 0.4  | 2         |
| 13 | Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. <i>Circulation</i> , <b>2019</b> , 140, 1960-1963   | 16.7 | 6         |
| 12 | Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2819-2828  | 15.1 | 34        |
| 11 | Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1509-1524  | 59.2 | 538       |
| 10 | Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox. <i>Clinical Cardiology</i> , <b>2019</b> , 42, 1028-1040  | 3.3  | 9         |
| 9  | Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5). <i>Russian Journal of Cardiology</i> , <b>2019</b> , 92-97                                      | 1.3  | 1         |
| 8  | Selection of P2Y12 antagonist in patients with myocardial infarction who received thrombolytic therapy. Results of annual follow-up of TREAT study patients. <i>Russian Journal of Cardiology</i> , <b>2019</b> , 64-70  | 1.3  |           |
| 7  | The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease. <i>Meditsinskiy Sovet</i> , <b>2019</b> , 34-41  | 0.4  |           |
| 6  | Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , <b>2018</b> , 202, 89-96 | 4.9  | 10        |
| 5  | Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 391-399   | 16.2 | 49        |
| 4  | Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 1322-1327  | 3.3  | 6         |

|   |  |     |                |
|---|--|-----|----------------|
| 3 | Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change?. <i>Russian Journal of Cardiology</i> , <b>2018</b> , 65-70  | 1.3 | 1              |
| 2 | Long-term follow-up of antithrombotic management patterns in patients with acute coronary syndrome in Russia: an observational study (EPICOR-RUS study). <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 1269-1276 | 2.5 | 1              |
| 1 | Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. <i>Cardiovascular Therapeutics</i> , <b>2016</b> , 34, 191-8                           | 3.3 | 5 <sup>1</sup> |